RARE
Price
$36.54
Change
+$0.09 (+0.25%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
3.52B
70 days until earnings call
Intraday BUY SELL Signals
SLNO
Price
$52.66
Change
+$1.94 (+3.82%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
2.72B
97 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RARE vs SLNO

Header iconRARE vs SLNO Comparison
Open Charts RARE vs SLNOBanner chart's image
Ultragenyx Pharmaceutical
Price$36.54
Change+$0.09 (+0.25%)
Volume$10.83K
Capitalization3.52B
Soleno Therapeutics
Price$52.66
Change+$1.94 (+3.82%)
Volume$30.18K
Capitalization2.72B
RARE vs SLNO Comparison Chart in %
RARE
Daily Signal:
Gain/Loss:
SLNO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RARE vs. SLNO commentary
Dec 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a Buy and SLNO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 05, 2025
Stock price -- (RARE: $36.45 vs. SLNO: $50.72)
Brand notoriety: RARE and SLNO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RARE: 146% vs. SLNO: 83%
Market capitalization -- RARE: $3.52B vs. SLNO: $2.72B
RARE [@Biotechnology] is valued at $3.52B. SLNO’s [@Biotechnology] market capitalization is $2.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RARE’s FA Score shows that 0 FA rating(s) are green whileSLNO’s FA Score has 0 green FA rating(s).

  • RARE’s FA Score: 0 green, 5 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, SLNO is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RARE’s TA Score shows that 5 TA indicator(s) are bullish while SLNO’s TA Score has 5 bullish TA indicator(s).

  • RARE’s TA Score: 5 bullish, 3 bearish.
  • SLNO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, RARE is a better buy in the short-term than SLNO.

Price Growth

RARE (@Biotechnology) experienced а +7.97% price change this week, while SLNO (@Biotechnology) price change was +2.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.21%. For the same industry, the average monthly price growth was +5.86%, and the average quarterly price growth was +56.03%.

Reported Earning Dates

RARE is expected to report earnings on Feb 12, 2026.

SLNO is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+1.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($3.52B) has a higher market cap than SLNO($2.72B). SLNO YTD gains are higher at: 12.836 vs. RARE (-13.359). SLNO has higher annual earnings (EBITDA): -176.1M vs. RARE (-435.33M). RARE has more cash in the bank: 477M vs. SLNO (287M). RARE has less debt than SLNO: RARE (36.3M) vs SLNO (52.8M). RARE has higher revenues than SLNO: RARE (610M) vs SLNO (32.7M).
RARESLNORARE / SLNO
Capitalization3.52B2.72B129%
EBITDA-435.33M-176.1M247%
Gain YTD-13.35912.836-104%
P/E RatioN/AN/A-
Revenue610M32.7M1,865%
Total Cash477M287M166%
Total Debt36.3M52.8M69%
FUNDAMENTALS RATINGS
RARE vs SLNO: Fundamental Ratings
RARE
SLNO
OUTLOOK RATING
1..100
135
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
40
Fair valued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
6188
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
21n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLNO's Valuation (40) in the Medical Specialties industry is somewhat better than the same rating for RARE (96) in the Biotechnology industry. This means that SLNO’s stock grew somewhat faster than RARE’s over the last 12 months.

SLNO's Profit vs Risk Rating (70) in the Medical Specialties industry is in the same range as RARE (100) in the Biotechnology industry. This means that SLNO’s stock grew similarly to RARE’s over the last 12 months.

SLNO's SMR Rating (98) in the Medical Specialties industry is in the same range as RARE (99) in the Biotechnology industry. This means that SLNO’s stock grew similarly to RARE’s over the last 12 months.

RARE's Price Growth Rating (61) in the Biotechnology industry is in the same range as SLNO (88) in the Medical Specialties industry. This means that RARE’s stock grew similarly to SLNO’s over the last 12 months.

RARE's P/E Growth Rating (100) in the Biotechnology industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that RARE’s stock grew similarly to SLNO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RARESLNO
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 10 days ago
87%
Declines
ODDS (%)
Bearish Trend 15 days ago
81%
Bearish Trend 15 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RARE
Daily Signal:
Gain/Loss:
SLNO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCMVX13.050.15
+1.16%
Fidelity Mid Cap Value K6
TRVLX50.140.56
+1.13%
T. Rowe Price Value
BRUFX575.412.98
+0.52%
Bruce
PABFX19.820.06
+0.30%
PGIM Balanced Z
CVTRX56.960.14
+0.25%
Calamos Growth & Income A

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been closely correlated with MREO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+8.90%
MREO - RARE
70%
Closely correlated
+12.00%
RGNX - RARE
49%
Loosely correlated
+5.49%
TRDA - RARE
48%
Loosely correlated
+2.23%
DNLI - RARE
47%
Loosely correlated
+6.50%
XNCR - RARE
47%
Loosely correlated
+8.26%
More

SLNO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with BRNS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNO
1D Price
Change %
SLNO100%
+5.41%
BRNS - SLNO
56%
Loosely correlated
+3.37%
BHVN - SLNO
39%
Loosely correlated
+3.28%
GRCE - SLNO
38%
Loosely correlated
+0.48%
SYRE - SLNO
36%
Loosely correlated
+13.38%
RARE - SLNO
35%
Loosely correlated
+8.90%
More